Physician profile
Larry Tran
NPI 1629259510
$22,232.84
in general payments reported to CMS, 2019-2025
75 companies · $4,094 in 2025
The $4,094 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,681 · 2020: $1,412 · 2021: $2,460 · 2022: $2,991 · 2023: $4,428 · 2024: $5,168 · 2025: $4,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,663.46 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,497.92 | 2020-2025 | Botox, Ubrelvy, Qulipta |
| Ucb, INC. | $1,592.76 | 2020-2025 | Rystiggo, Briviact, Fintepla |
| Novartis Pharmaceuticals Corporation | $1,583.88 | 2019-2025 | |
| Pfizer INC. | $1,180.22 | 2019-2025 | |
| Sk Life Science, INC. | $1,139.02 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,109.47 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $875.88 | 2020-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $796.61 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Emd Serono, INC. | $723.07 | 2021-2025 | Mavenclad |
| Acadia Pharmaceuticals INC | $663.61 | 2020-2025 | Nuplazid |
| Amgen INC. | $580.95 | 2019-2025 | Uplizna, Aimovig |
| Lilly USA, LLC | $526.02 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Acorda Therapeutics, INC | $490.83 | 2019-2023 | Ampyra, Inbrija |
| Allergan, INC. | $484.59 | 2019-2022 | |
| Genzyme Corporation | $459.46 | 2019-2024 |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.